Cellectar Biosciences (CLRB) Competitors $4.88 -0.05 (-1.01%) Closing price 04:00 PM EasternExtended Trading$4.89 +0.01 (+0.12%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. LVTX, ATHE, TELO, RNTX, KALA, LTRN, KZR, OKUR, ESLA, and BDRXShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include LAVA Therapeutics (LVTX), Alterity Therapeutics (ATHE), Telomir Pharmaceuticals (TELO), Rein Therapeutics (RNTX), KALA BIO (KALA), Lantern Pharma (LTRN), Kezar Life Sciences (KZR), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Its Competitors LAVA Therapeutics Alterity Therapeutics Telomir Pharmaceuticals Rein Therapeutics KALA BIO Lantern Pharma Kezar Life Sciences OnKure Therapeutics Estrella Immunopharma Biodexa Pharmaceuticals LAVA Therapeutics (NASDAQ:LVTX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership. Which has higher earnings & valuation, LVTX or CLRB? LAVA Therapeutics has higher revenue and earnings than Cellectar Biosciences. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLAVA Therapeutics$11.98M2.99-$25.11M-$1.04-1.31Cellectar BiosciencesN/AN/A-$44.58M-$21.92-0.22 Is LVTX or CLRB more profitable? LAVA Therapeutics' return on equity of -86.38% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets LAVA TherapeuticsN/A -86.38% -34.12% Cellectar Biosciences N/A -619.70%-158.04% Do insiders & institutionals hold more shares of LVTX or CLRB? 16.4% of Cellectar Biosciences shares are owned by institutional investors. 9.5% of LAVA Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend LVTX or CLRB? LAVA Therapeutics presently has a consensus price target of $3.17, suggesting a potential upside of 132.84%. Cellectar Biosciences has a consensus price target of $375.00, suggesting a potential upside of 7,584.43%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk and volatility, LVTX or CLRB? LAVA Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Does the media refer more to LVTX or CLRB? In the previous week, LAVA Therapeutics and LAVA Therapeutics both had 1 articles in the media. LAVA Therapeutics' average media sentiment score of 1.89 beat Cellectar Biosciences' score of 0.95 indicating that LAVA Therapeutics is being referred to more favorably in the media. Company Overall Sentiment LAVA Therapeutics Very Positive Cellectar Biosciences Positive SummaryLAVA Therapeutics beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks. Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.92M$10.60B$5.61B$9.11BDividend YieldN/A2.07%5.24%4.01%P/E Ratio-0.2211.1919.7619.92Price / SalesN/A30.15430.8999.65Price / CashN/A22.9637.4658.16Price / Book0.543.668.045.49Net Income-$44.58M$235.43M$3.18B$250.27M7 Day Performance1.22%1.27%3.72%4.78%1 Month Performance-61.89%1.79%3.72%7.20%1 Year Performance-93.41%-14.57%29.92%17.27% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences2.2598 of 5 stars$4.88-1.0%$375.00+7,584.4%-93.0%$8.92MN/A-0.2210LVTXLAVA Therapeutics1.4492 of 5 stars$1.32flat$3.17+139.9%-29.3%$34.72M$4.99M-1.2760ATHEAlterity Therapeutics2.2595 of 5 stars$3.87-6.7%$12.00+210.1%+101.6%$34.32MN/A0.0010Gap UpTrading HaltedTELOTelomir Pharmaceuticals3.5948 of 5 stars$1.15flat$15.00+1,204.3%-72.5%$34.22MN/A-2.741Positive NewsRNTXRein TherapeuticsN/A$1.54+2.0%N/AN/A$34.12MN/A-0.549KALAKALA BIO3.9718 of 5 stars$5.28+3.5%$13.50+155.7%-9.2%$34.06M$3.89M-0.6430News CoverageAnalyst ForecastLTRNLantern Pharma3.1487 of 5 stars$3.15-3.1%$25.00+693.7%-15.0%$33.96MN/A-1.7120Positive NewsHigh Trading VolumeKZRKezar Life Sciences4.2834 of 5 stars$4.55-0.7%$39.50+768.1%-15.6%$33.26M$7M-0.4260Positive NewsOKUROnKure Therapeutics3.5874 of 5 stars$2.39+0.4%$32.33+1,252.9%N/A$32.29MN/A-0.45N/AESLAEstrella Immunopharma2.3484 of 5 stars$0.88+0.2%$16.00+1,714.7%-28.9%$31.89MN/A-3.39N/ABDRXBiodexa Pharmaceuticals0.0802 of 5 stars$0.87+0.8%N/AN/A$31.63MN/A0.0020Positive News Related Companies and Tools Related Companies LVTX Alternatives ATHE Alternatives TELO Alternatives RNTX Alternatives KALA Alternatives LTRN Alternatives KZR Alternatives OKUR Alternatives ESLA Alternatives BDRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
